ITCC-080 Entrectinib
PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB (RXDX-101) IN CHILDREN AND ADOLESCENTS WITH NO CURATIVE FIRST-LINE TREATMENT OPTION, RECURRENT OR REFRACTORY SOLID TUMORS AND PRIMARY CNS TUMORS
Promotor Name : Hoffmann-La Roche
Investigator Name : Dr Birgit GEOERGER
Trial registered on clinicaltrial.gov: NCT02650401
